Claire Taylor charity dinner success

editorial image

A charity dinner in memory of Claire Taylor was held in Kirriemuir Town Hall recently to raise funds for the Juvenile Diabetes Research Forum.

Claire (17) died in November 2012 of undiagnosed type 1 diabetes.

The main speaker was the Scottish mountaineer, Jamie Andrew, who lost his limbs as a result of frostbite following a tragic mountaineering accident.

He gave an inspiring, moving and motivational account of the accident and his life since then. Humour for the evening was provided by Bill Copeland, retired Glasgow lawyer, and Claire Douglas from the JDRF provided an insight into the support the JDRF gives to those with Type 1 diabetes and the current exciting advances in research for the treatment of it.

The evening was well supported by individuals and businesses alike and the sum of £11,800 was raised. Claire’s family would like to sincerely thank all those who helped make the evening such a success.

Type 1 diabetes is a chronic, life-threatening and lifelong condition. It is caused by a problem with the immune system, is not caused by lifestyle and cannot currently be prevented. In people with type 1 diabetes, the body mistakenly attacks the insulin-producing cells in the pancreas meaning that little or no insulin is produced. As a result, the body cannot convert glucose from food into the energy the body needs to survive. Just to stay alive, people with type 1 diabetes rely on multiple daily insulin injections (or pump infusions) and finger prick blood tests. But insulin is not the cure and does not prevent the devastating impact of the condition on children, adults and families living with it.

JDRF is totally focused on type 1 diabetes, and is run by people with type 1, for people with type 1. JDRF is a global organisation working towards the cure. Internationally, it is the world’s leading provider of charitable funds for type 1 diabetes research.

It works with academia, industry and governments to make sure that the research funded has the greatest possible impact on the lives of people with type 1, now and in the future.